Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 |
| clinicaltrials |
| NCT05061134 | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition(MONETTE) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 11 | Jul 31, 2025 | clinicaltrials |
| NCT04616443 | OH2 Injection in Combination With HX008 for Melanoma. | recruiting | Phase 1 / Phase 2 | 60 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT02553642 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05304546 | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma(MK3475-C01) | completed | Phase 2 | 1 | Dr. Ronnie ShapiraOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | completed | Phase 1 / Phase 2 | 110 | Hoffmann-La RocheINDUSTRY | 5 | Jul 18, 2025 | clinicaltrials |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma(TebeMRD) | active not recruiting | Phase 2 | 850 | University of OxfordOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04493203 | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | completed | Phase 2 | 31 | Yana NajjarOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Thomas Jefferson UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06508827 | Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06560905 | Preoperative Planning With PSMA-PET in Melanoma Surgery Trial(PPPIMS) | recruiting | Phase 2 | 16 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1(REVERT) | not yet recruiting | Phase 1 / Phase 2 | 41 | Oncodesign Precision MedicineINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT01378975 | A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 10 | Jun 25, 2025 | clinicaltrials |
| NCT05388851 | Education for Prevention of Melanoma in Hispanic Populations | terminated | Phase 2 | 145 | Mayo ClinicOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04698187 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | terminated | Phase 2 | 44 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02743819 | Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma | active not recruiting | Phase 2 | 70 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6(ARTISTRY-6) | terminated | Phase 2 | 173 | Mural Oncology, IncINDUSTRY | 8 | Jun 10, 2025 | clinicaltrials |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | completed | Phase 1 / Phase 2 | 41 | BiogenINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | withdrawn | Phase 2 | 0 | BiogenINDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT03898908 | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain(EBRAIN-MEL) | completed | Phase 2 | 48 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | Krystal Biotech, Inc.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT00661622 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | completed | Phase 2 | 53 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT03618641 | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | completed | Phase 2 | 34 | Diwakar DavarOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT01864538 | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | terminated | Phase 2 | 11 | ImmunoGenesisINDUSTRY | 2 | May 11, 2025 | clinicaltrials |
| NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | completed | Phase 2 | 77 | Seagen Inc.INDUSTRY | 6 | May 11, 2025 | clinicaltrials |
| NCT06965231 | Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial(FUMS-EDJS2024) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03719131 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | active not recruiting | Phase 2 | 15 | Emory UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT02875132 | Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma | completed | Phase 2 | 9 | Chinese University of Hong KongOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT01355120 | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease(DeCOG) | completed | Phase 2 | 171 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02523313 | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | completed | Phase 2 | 167 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02902029 | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(ImmunoCobiVem) | completed | Phase 2 | 186 | University Hospital, EssenOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT06797297 | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy | recruiting | Phase 2 | 180 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor | terminated | Phase 2 | 14 | Yonsei UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05483400 | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors(TIRACAN) | recruiting | Phase 2 | 97 | University Medical Center GroningenOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2025source: clinicaltrials